Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431124 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL30571418 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL12897943 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL18269413 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL3221050 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL245092 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL13625375 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL14669553 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL30571404 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL13764732 | 1.00 | HMGCR (0.74) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434067-B2 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | HANMI PHARM. CO., LTD. (KR) | 2019-10-08 | — | — | US | claimed |
| US-20160346213-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | HANMI PHARM. CO., LTD. (KR) | 2016-12-01 | — | — | US | claimed |
| EP-3089739-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | Hanmi Pharm. Co., Ltd. (KR) | 2016-11-09 | — | — | EP | claimed |
| WO-2015102400-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | WO | claimed |
| EP-4710920-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN | Adamed Pharma S.A. (PL) | 2026-03-18 | — | — | EP | disclosed |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| EP-3454838-B1 | PHARMACEUTICAL COMPOSITION | ADAMED PHARMA S A (PL) | 2020-02-12 | — | — | EP | disclosed |
| US-20190315696-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | API CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10434067-B2 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | HANMI PHARM. CO., LTD. (KR) | 2019-10-08 | — | — | US | disclosed |
| WO-2019182276-A1 | PHARMACEUTICAL COMBINATION PREPARATION COMPRISING EZETIMIBE AND ROSUVASTATIN | HANMI PHARM. CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| US-10377722-B2 | Rosuvastatin calcium and process for producing intermediate thereof | API CORPORATION (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070155765-A1 | Method of preparation of the hemi-calcium salt of (e)-7-[4-(4fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonvl)aminolpyrimidin-5-yl](3r,5s)-3,5-, dihvdroxy-6-heptenoic acid | ZENTIVA, A.S. (CZ) | 2007-07-05 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7183285-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070015779-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7163945-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, TNNI3, TNNT2 | HMGCR 18/4885 |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | HMGCR, DHCR7, FADS2 | HMGCR 1/4885 |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885 |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | FABP3, TNNI3, TNNT2 | HMGCR 16/4885 |
| US-10377722-B2 | Rosuvastatin calcium and process for producing intermediate thereof | HMGCR, COASY, PCSK9 | HMGCR 1/4885 |
| US-20190315696-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | HMGCR, COASY, PCSK9 | HMGCR 1/4885 |
| US-20070015779-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885 |
| US-20070155765-A1 | Method of preparation of the hemi-calcium salt of (e)-7-[4-(4fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonvl)aminolpyrimidin-5-yl](3r,5s)-3,5-, dihvdroxy-6-heptenoic acid | HRH4, HRH3, CACNA1E | HMGCR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.